Genmab A/S Stock

Genmab A/S EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Genmab A/S (GMAB.CO) as of Aug 21, 2026 is 15.46. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 13.00 — a change of 18.87% (higher).

EV/EBITDA

15.46

YoY

18.87%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Genmab A/S is 2026 15.46 . EV/EBITDA (Enterprise Value to EBITDA) of Genmab A/S was 2025 13.00 . It decreases by 18.87% higher compared to the previous year.
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

EV/EBITDA (Enterprise Value to EBITDA) of Genmab A/S is 15.46 in 2026.

EV/EBITDA (Enterprise Value to EBITDA) of Genmab A/S changed from 13.00 to 15.46, representing a 18.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Genmab A/S with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Genmab A/S

All Key Metrics — Genmab A/S